Sparse-fur (spf) mouse as a model of hyperammonemia: Alterations in the neurotransmitter systems

Advances in Experimental Medicine and Biology

Volumn 420, Issue , 1997, Pages 143-158

  Qureshi, I A ^a   Rama Rao, K V ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMMONIA; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; CARNITINE; CHOLINERGIC RECEPTOR; EXCITOTOXIN; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; ORNITHINE CARBAMOYLTRANSFERASE; SEROTONIN; SEROTONIN RECEPTOR; TRYPTOPHAN;

AMINO ACID BLOOD LEVEL; AMMONIA BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREEDING; CARNITINE DEFICIENCY; CHOLINERGIC SYSTEM; CONFERENCE PAPER; ENERGY METABOLISM; ENZYME DEFICIENCY; HYPERAMMONEMIA; MITOCHONDRIAL ENERGY TRANSFER; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; RESPIRATORY CHAIN; UREA CYCLE; X CHROMOSOME LINKAGE;

ANIMALIA;

EID: 0030846740     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5945-0_9     Document Type: Conference Paper

References (32)

1. I.A. Qureshi, J. Letarle, and S.R. Qureshi, Congenital hyperammonemia (Model No. 235), in: Handbook of Animal Models of Human Disease, C. C. Capen, D. B Hackle, T. C Jones, G. Migaki ed., Fase 11. Washington, D.C: Registry of Comparative Pathology, pp 2-4 (1981).
2. M.L. Batshaw, S.L. Hyman, C. Bachmann, I.A. Qureshi and J.T. Coyle, Animal Models of congenital hyperammonemia, in: Animal Models of Dementia, J.T.Coyle, ed., Alan. R. Liss, Inc, New York, pp 163-198 (1987).
3. I.A. Qureshi, Congenital hyperammonemia (Model No. 235) Supplemetal Update, in: Handbook of Animal Models of Human Disease, C. C. Capen, D. B Hackle, T. C Jones, G. Migaki, ed., Fase 11. Washington, D.C: Registry of Comparative Pathology, pp 1-2 (1989).
4. I.A. Qureshi, Animal models of hereditary hyperammonemias, in: Neuromethods, Animal Models of Neurological Disease, II, A. Boulton., G. Baker and R. Butterworth, ed., The Humana Press Inc, New York pp 329-356 (1992).
5. R. Demars, S.L. LeVan, B.L. Trend and L.B. Russel, Abnormal ornithine carbamoyl-transferase in mice having the sparse-fur mutation. Proc. Natl. Acad. Sci, U.S.A. 73:1693-1698 (1976).
6. I. A. Qureshi, J. Letarte and R. Quellet, Spontaneous animal models of ornithine transcarbamylase deficiency: Studies on serum and urinary nitrogen metabolites, in: Urea Cycle Diseases, A. Lowenthal, A. Mori and B. Marecau, ed., Plenum Press, New York, pp 173-183 (1983).
7. M.L. Batshaw, M. Yudkoff, B.A. McLaughlin, E. Gorry, NJ. Anegawa, I.A.S. Smith and M.B. Robinson, The sparse-fur mouse as a model of gene therapy in ornithine carbamoyltransferase deficiency, Gene Therapy. 2:743-749 (1995).
8. J.C. Pages, M. Andreoletti, M. Bennoun, C. Vons, J. Elcheroth, P. Lehn, D. Houssin, J. Chapman, P. Briand, R. Benarous, D. Franco and A. Weber, Efficient retroviral-mediated gene transfer into primary cultures of murine and human hepatocytes: Expression of LDL receptor, Human Gene Therapy 6:21-30 (1995).
9. S.E. Raper, Hepatocyte transplantation and gene therapy, Clin Transplantation. 9:249-254 (1995).
10. M.A. Morsy and C.T. Caskey, Ornithine transcarbamylase deficiency: A model for gene therapy, in: Hepatic Encephalopathy, Hyperammonemia, and Ammonia Toxicity, V. Felipo and S. Grisolia, ed., Plenum Press, New York, pp 145-154 (1994).
11. M.A. Morsy, J.Z. Zhao, T.T. Ngo, A.W. Warman, W.E. O'Brien and F.L. Graham, Patient selection may affect gene therapy success, J. Clin. Invest. 97:826-831 (1996).
12. X. Ye, M.B. Robinson, M.L. Batshaw, E.E. Furth, I. Smith and J.M. Wilson, Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors, J. Biol. Chem. 271:3639-3646 (1996).
13. I.A. Qureshi, J. Letarte and R. Quellet, Ornithine transcarbamylase deficiency in mutant mice I. Studies on the characterization of enzyme defect and suitability as animal model of human disease, Pediat. Res. 13:807-811 (1979).
14. G. Veres, R.A. Gibbs, S.E. Scherer and C.T. Caskey, The molecular basis of sparse-fur mouse mutation, Science. 237:415-417(1987).
15. ash mice, Biochem. J. 257:251-257 (1989).
16. P. Briand, S. Mirira, M. Mori, L. Cathelineau, P. Kamoun and M. Talibana, Cell-free synthesis and transport of precursors of mutant ornithine carbamoyltransferases into mitochondria, Biochem. Biophys. Acta, 760:389-397(1983).
17. ash mice: Genes, mRNA and mRNA precursors, Biochem. Biophys. Res. Commun. 146:1064-1070 (1987).
18. N. Dubois, C. Cavard, J.F. Chasse, P. Kamoun and P. Briand, Compared expression of ornithine transcarbamylase and carbamyl phosphate synthetase in liver and small intestine of normal and mutant mice, Biochim. Biophys. Acta. 950:321-328 (1988).
19. Y.R. Mawal, K.V. RamaRao and I.A. Qureshi, Enhanced expression of hepatic mitochondrial urea cycle enzymes and cytochrome C oxidase with chronic acetyl-L-carnitine treatment in spf mice with ornithine transcarbamylase deficiency, J. Biol. Chem. (submitted) (1996).
20. A. Russel, B. Levin, V.G. Oberholzer and L. Sinclair, Hyperammonemia. A new instance of an inborn enzymatic defect of the biosynthesis of urea, Lancet. 2:699-700 (1962).
21. E.M. Short, HO. Conn, P.J. Snodgrass, A.G.M. Campbell and L.E. Rosenberg, Evidence for X-linked dominant inheritance of ornithine transcarbamylase deficiency, N. Engl. J. Med. 288:7-12 (1973).
22. P. Briand, B. Francois, D. Rabier and L. Cathelineau, Omithine transcarbamylase deficiencies in human males: Kinetic and immunochemical classification, Biochem. Biophys. Acta. 704:100-106 (1982).
23. I.A. Qureshi, J. Letarte and R. Quellet, Expression of ornithine tianscarbamylase deficiency in the small intestine and colon of sparse-fur mutant mice, J. Pediatr. Gastroenterol. Nutr. 4:118-124 (1985).
24. E.B. Spector and R.A. Mazzochi, The sparse-fur mouse: An animal model for a human inborn error of metabolism of the urea cycle, in: Orphan Drugs and Orphan Diseases: Clinical Realities and Public Policy, Alan R. Liss, Inc, New York, pp 86-96 (1983).
25. I.A. Qureshi, J. Letarte and R. Ouellet, Activity of orotate metabolizing enzyme complex and various urea cycle enzymes in mutant mice with ornithinc trans-carbamylase deficiency, Experientia. 38:308-309 (1982).
26. S. Vasudevan, I.A. Qureshi, L. Mores, P.M. Rao, S. Rajalakshmi and D.S.R. Sarma, Abnormal hepatic nucleotide pools in sparse-fur (spl) mutant mice deficient in ornithine transcarbamylase, Biochem Med. Metabol. Biol. 47:274-278(1992).
27. L. Vasudevan, I.A. Qureshi, M. Lambert, P. Rao, S. Rajalakshmi and D.S.R. Sarma, Nucleotide pool imbalances in the livers of patients with urea cycle disorders associated with increased levels of orotic acid, Biochem. Mol. Biol. Int. 35:685-690 (1995).
28. I.A. Qureshi, J. Letarte, S. Lebel and R. Ouellet, Variablite de l'active enzymatique et de l'acidurie orotique chez les souris spf/+ heterozygotes deficientes en ornithine transcarbamylase, Diabete. Metabolisme. 12:250-255 (1986).
29. J.C. Feoli-Fonscca, M. Lambert, G. Mitchell, S.B. Melançon, L. Dallaire, D.S. Millington and I.A. Qureshi, Chronic sodium benzoate therapy in children with inborn errors of urea synthesis: Effect on carnitine metabolism and ammonia nitrogen removal, Biochem. Mol. Med. 57:31-36 (1996).
30. A. Michalak and I.A. Qureshi, Carnitine musculaire chez les souris hyperammoniémiques: effect du traitement au benzoate de sodium, Can. J. Physiol. Pharmacol. 71:439-446 (1990).
31. A. Michalak and I.A. Qureshi, Profil des acylcamitines hepatiques et musculares chez les souris chroniquement hyperammonemiques apres un traitment aigu avec le benzoate de sodium: etudes dose-response, Ann Biol Clin. 50:879-885 (1993).
32. I. Inoue, T. Gushiken, K. Kobayashi and T. Saheki, Accumulation of large neutral amino acids in the brains of sparse-fur mice at hyperammonemic state, Biochem Med. Metabol. Biol. 38:378-386 (1987).